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Delineating the Genetic Basis Review
of Systemic Lupus Erythematosus
though this definition creates a phenotypically heteroge-
neous classification of SLE, nearly all patients with bona
fide SLE have elevated titers of antibodies to nuclear
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5323 Harry Hines Boulevard (ANA) testing is very sensitive for diagnosing the dis-
Dallas, Texas 75235 ease, although not highly specific since ANA antibodies
2 Department of Medicine are sporadically detected in as much as 2% of the female
Center for Immunology population over the age of 40. Antibodies to double-
University of Minnesota Medical School stranded DNA and the Sm protein, on the other hand,
312 Church Street, SE are observed essentially only in SLE and, when present,
Minneapolis, Minnesota 55455 are useful in establishing the diagnosis. In addition, high
erythrocyte sedimentation rates, elevated serum levels
of acute phase reactants, and low levels of C3 and C4
Summary complement components often accompany active dis-
ease. Current treatments for SLE include the anti-malar-
Genetic predisposition plays a crucial role in suscepti- ial hydroxychloroquine, steroids, and cytotoxic drugs
bility to systemic lupus erythematosus (SLE) in both such as methotrexate and cyclophosphamide. Although
human patients and animal models. Recent progress these therapies allow management of disease severity
in experimental systems and human linkage analysis for many patients, a variety of deleterious side effects
is providing key insights into the genetic basis for associated with these drugs together with therapy-resis-
susceptibility and elucidating the manner in which ge- tant disease symptoms significantly diminish the quality
netic interactions mediate severe disease pathogene- of life for many SLE patients.
sis. Genes in multiple pathways appear to participate The worldwide incidence of SLE is conservatively esti-
in specific elements of the disease, and epistatic inter- mated as between 12 and 64 cases per 100,000 individu-
actions among these genes play an important role in als, with a striking 9:1 female gender bias and at least
both aggravating and suppressing disease devel-
2- to 4-fold higher incidence in non-Caucasian as com-
opment.
pared with Caucasian populations (Hochberg, 1997a).
There are more than 364,000 women in the US diag-
Introduction
nosed with SLE, and possibly an equal number whoSystemic lupus erythematosus (SLE) is a chronic auto-
fulfill two or three of the 11 criteria, but are not diagnosedimmune disorder, classically depicted as a systemic au-
with SLE. Further, the incidence of disease appears totoimmune disease caused by the production of patho-
be increasing. Although the factors responsible for thegenic autoantibodies to a spectrum of nuclear antigens.
initiation of SLE are poorly understood, genetic predis-SLE in humans manifests with a diverse array of clinical
position is firmly established as a key element in suscep-symptoms that potentially involve multiple organ sys-
tibility. Strong familial aggregation in SLE is documentedtems. This heterogeneity reflects direct autoantibody-
by s estimates for the disease that are well in excessmediated tissue injury as well as blood vessel inflamma-
of 15, indicating that siblings of SLE patients have ation (termed vasculitis) caused by the deposition of com-
much greater relative risk for disease in comparisonplement-fixing immune complexes. A typical patient
to the population as a whole (Hochberg et al., 1985;with SLE is a young woman in her child-bearing years
Lawrence et al., 1987). In addition, the multigenic naturewho presents with intermittent fatigue, joint pain and
of SLE susceptibility is indicated by the 10-fold higherswelling, skin rashes, low white blood cell count, and
rate of concordance for SLE in monozygotic twin pairschest pains due to pleuritis (see Table 1). Approximately
(34%) compared with dizygotic pairs (3%) (Block et al.,one-half of lupus patients will manifest the more severe
1975; Deapen et al., 1992).complications of the disease, which can include nephri-
The genetic basis for susceptibility to SLE has beentis, central nervous system vasculitis, pulmonary hyper-
the subject of intense investigation during the last de-tension, interstitial lung disease, and stroke. In addition
cade and, although the complexity of systemic autoim-to systemic lupus, there are types of lupus that involve
munity remains daunting, several new insights haveonly the skin, as well as a subtype of the systemic dis-
been obtained both via the analysis of animal modelsease caused by certain medications (drug-induced
and through linkage analysis in human patient popula-lupus).
tions. In addition, recent advances in our understandingThe diagnosis of SLE is complicated by these exten-
of the human and mouse genomes are providing toolssive variations in clinical symptoms. Current diagnostic
guidelines require that patients fulfill any four of 11 crite- that will significantly enhance future analyses of com-
ria to be diagnosed with the systemic form of SLE plex traits such as SLE susceptibility. Here, we will
(Hochberg, 1997b; Tan et al., 1982) (see Table 1). Al- briefly overview our current understanding of the genet-
ics of both human and murine lupus and discuss strate-
gies and technologies that will impact the future of ge-3 Correspondence: edward.wakeland@email.swmed.edu (E.K.W.),
behre001@umn.edu (T.W.B.) netic analysis of SLE.
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ciation data, and ultimately in localizing the genetic ef-Table 1. Criteria for the Diagnosis of Human SLE
fect, is posed by the significant linkage disequilibrium
Category Symptom
(LD) across the region. LD refers to the frequency with
Skin criteria Butterfly rash (over the cheeks and nose) which specific sets or “haplotypes” of alleles persist in
Discoid rash (scarring rash in sun-exposed a population. The reported associations with SLE of
areas) several MHC class III genes, including TNFalpha, the
Photosensitivity
TAP genes, and HSP70, may reflect LD with other genesOral ulcerations
in the HLA or the epistatic effects of several genes onSystemic criteria Arthritis (nondeforming)
extended haplotypes.Pleuritis or pericarditis
Proteinuria or cellular urinary casts
Seizures or psychosis with no other etiology Fc Receptors
Laboratory criteria Hemolytic anemia, leukopenia, lymphopenia, The Fc receptors FcRI (CD64), FcRII (CD32), and
or thrombocytopenia
FcRIII (CD16) function to bind and clear IgG antibodiesAnti-DNA antibodies, anti-Sm antibodies,
and IgG-containing immune complexes from the circula-VDRL false syphilis test, lupus anticoagu-
tion. Recent studies have shown that a greater propor-lant, or antiphospholipid antibodies
Antinuclear antibodies (ANA) tion of African-American SLE patients are heterozygous
or homozygous for the IgG2 low binding FcRIIa-R131Any four of the eleven criteria establish the diagnosis of SLE; revised
allele, with further enrichment observed in patients with1997 American College of Rheumatology (Hochberg, 1997).
lupus nephritis (Salmon et al., 1996). A low binding allele
of the FcRIIIa, which functions to bind and clear IgG1-
or IgG3-bearing immune complexes, is also associatedCandidate Genes in Human SLE
with SLE and SLE nephritis (Wu et al., 1997). The FcGiven the evidence for a strong genetic influence in
receptors are very tightly clustered at 1q23, and theSLE, there are hundreds of published studies that have
interpretation of these results is potentially complicatedattempted to identify candidate genes contributing to
by LD in the region. Taken together, however, the avail-the SLE phenotype (reviewed in Gaffney et al., 2001;
able evidence is consistent with one or more of the FcHarley et al., 1998; Schur, 1995). The majority of these
receptor genes contributing to human SLE.studies have used classic case/control association
methodologies. Although association studies are pow-
Complementerful, they are subject to the problems of population
The complement system consists of approximately 20admixture and genetic drift, where differences in allele
plasma proteins that function to mediate inflammatoryfrequencies between patient populations and control
responses to immune complexes and to assist in thesubjects may reflect differences in population history
clearance of various infectious microbes (Schur, 1995).rather than true disease association. Because of admix-
For years, a strong relationship has been noted for defi-ture and small sample sizes, many of the genes impli-
ciencies of early classical pathway complement compo-cated over the years in SLE have not been confirmed and
nents (C1q, C2, and C4) and the development of SLE
remain controversial. However, the available evidence
(reviewed in Carroll, 1998b; Schur, 1995). Homozygous
supports a role for the HLA region, complement compo-
C1q deficiency is a very rare disorder, and patients suffer
nents, and low affinity receptors for IgG in the predispo- from a particularly severe form of SLE with glomerulone-
sition to human SLE. phritis and skin manifestations, beginning in the first or
second decade of life (Bowness et al., 1994). Deficienc-
HLA ies of C2 and C4 also predispose to SLE (reviewed in
The human leukocyte antigen (HLA) region, spanning Schur, 1995). Both these complement proteins are en-
3.6 million base pairs of DNA at 6p21.3, is a gene-rich coded by genes in the HLA class III region. Complete
and transcriptionally active segment that encodes C2 or C4 deficiencies are rare (one in 10,000 for C2, less
scores of immunologically important genes, including than one in 10,000 for C4) and are often associated with
the highly polymorphic MHC class I and class II genes a mild form of lupus limited to skin and joint involvement
(Caron et al., 2001; Dawkins et al., 1999). Not surpris- (Arnett and Reveille, 1992). Documenting deficiencies in
ingly, HLA genes have received significant attention in the C4 genes is complicated by the fact that there are
human SLE, and there is evidence supporting a role for two isotypes of C4—C4A and C4B. Each C4 isotype has
specific extended HLA haplotypes spanning the MHC numerous allelic variants, and null alleles for each have
class II region as genetic risk factors for disease expres- also been identified. A C4A null allele is transmitted as
sion in several populations. The DR-B1 alleles DR2 and part of the extended HLA-A7, B8, DR3 haplotype, which,
DR3 have shown consistent associations with SLE in as noted above, is associated with SLE in Caucasian
European-Caucasian populations, with a 2- to 3-fold populations (Schur, 1995; Schur et al., 1990). Associa-
increase in the frequency of these two alleles compared tion studies in African-American and Asian populations,
with controls. HLA associations in many non-Caucasian where the null alleles are present on different class II
populations, both in the United States and around the haplotypes, indicate that these C4 alleles are indepen-
world, have not been very convincing or reproducible. dent risk factors for SLE (Howard et al., 1986; Yamada
Interestingly, DR/DQ alleles show stronger association et al., 1990).
with the autoantibody profiles observed in SLE than with
disease expression itself or individual clinical manifesta- Genetic Linkage Studies in Human SLE
tions (Schur, 1995). In the early 1990s, several groups initiated efforts to
identify the primary susceptibility genes in human SLEA significant challenge in interpreting these HLA asso-
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Table 2. Key Characteristics of the Published Human SLE Genome Screens
Number of Families, Avg. Reported Shared Unique
Individuals, SLE Family Primary Method Intermarker Risk Loci Risk Loci1 Risk Loci2
Study Patients Ethnicity of Analysis Distance (total #) (total #) (total #)
Minnesota (MN)3 187 Families 148 Caucasian Nonparametric 8.9 cM 18 10 8
656 Individuals 17 African-Am. multipoint linkage
399 SLE Pts. 13 Hispanic
9 Other
Oklahoma (OK)4 126 Families 77 Caucasian Model-based two point 10 cM 16 7 9
744 Individuals 40 African-Am. linkage/Regression
295 SLE Pts. 9 Other analyses
Southern Cal. (USC)5 80 Families 43 Hispanic Nonparametric 12 cM 11 7 4
434 Individuals 37 Caucasian multipoint linkage
188 SLE Pts.
Sweden (SW)6 17 Families 11 Swedish Model-based two 10 cM 13 3 10
201 Individuals 6 Icelandic point linkage
44 SLE Pts.
1 A shared risk locus is a susceptibility locus that is within 10 cM of another reported SLE locus.
2 A unique risk locus is a susceptibility locus with no other reported SLE locus within 10 cM.
3 (Gaffney et al., 1998; Gaffney et al., 2000).
4 (Moser et al., 1998; Gray-McGuire et al., 2000).
5 (Shai et al., 1999).
6 (Lindqvist et al., 2000).
families using emerging gene mapping methods. A ma- gene in the OK collection. Similar to the results from the
FcRIIa association studies, this effect is enriched injor hurdle was to recruit sufficient numbers of genetically
informative families enriched for systemic lupus. This African-American families. Supporting evidence for link-
age in the region was provided by the USC group. Thewas challenging given the relatively low frequency of
the disease in the population (1:2,000) and the difficul- interval at 1q41-42 shows evidence for linkage in nearly
all of the SLE mapping studies reported to date. Thisties in establishing a definitive diagnosis of SLE (see
above). Rheumatologists provide medical care for nearly locus was originally identified by Tsao et al. (1997), and
the effect here was localized close to the poly-ADP rbo-all SLE patients, and they have been extremely generous
with their time in assisting the various recruitment ef- syl transferase (PARP) gene, based on strong transmis-
sion disequilibrium test (TDT) results with a polymorphicforts. Hundreds of families with two or more SLE cases
have now been identified and collected. marker in the 5 region of the gene (Tsao et al., 1999).
Recent fine mapping in 210 sib pair and 122 trio familiesTo date, there are six published genome-wide screens
in SLE families, performed at four different sites. Some from the MN collection has localized the gene in this
region just centromeric to PARP near the D1S490 markerof the key features of these studies are shown in Table
2. The 187 University of Minnesota (MN) pedigrees are (Graham et al., 2001). This region has also been of inter-
est due to synteny of this region with the mouse Sle1dlargely Caucasian (80%) and are exclusively sib-pair
families (affected sibs plus all available parents) (Gaffney locus. In humans, it appears that there are two distinct
genetic effects in the 1q41-2 region—one centromericet al., 1998, 2000). The 126 families of the Oklahoma
Medical Research Foundation (OK) collection contain a to PARP at 1q41, and the other closer to the end of the
chromosome at 1q42.significant percentage of African-American pedigrees
(32%) and about an equal number of sib-pair and ex- The locus at 2q37 showed very strong evidence for
linkage in the Swedish and Icelandic families with a LODtended pedigrees (Moser et al., 1998; Gray-McGuire et
al., 2000). The University of Southern California (USC) of 4.24. Weaker signals were observed nearby in the OK
and MN studies, but this could be a locus of particularcollection consists of 80 sib-pair families, over half of
which are of Mexican-American ancestry (Shai et al., importance to Scandinavian families. The 4p15 region
(marker D4S2366) showed strong evidence for linkage1999). The University of Uppsala collection in Sweden
(SW) consists of 17 large, extended families collected in the OK family collection and was most strikingly dem-
onstrated when a new logistic regression algorithm wasin Iceland and Sweden (Lindqvist et al., 2000). In addition
to these screens, a group at UCLA has performed a applied to the OK dataset (Gray-McGuire et al., 2000).
This same marker was subsequently typed in the MNtargeted study examining the evidence for linkage in the
1q41 region, using a collection of 124 multiplex and collection and provided supportive evidence for linkage
(LOD  1.50) (Gray-McGuire et al., 2000). There are asimplex families of mixed ethnicity (Tsao et al., 1997,
1999). Altogether, these screens have identified 48 dis- number of interesting candidate genes in the region,
including CD38, BST1, and ZNF36.tinct chromosomal loci that show at least nominal evi-
dence for linkage in human SLE. Of these, six regions The locus on chromosome 6p21 includes the HLA
region, with the strongest evidence for linkage observedmeet criteria for “significant” linkage (LOD score  3.3),
as defined by Lander and Kruglyak (1995) (see Table 3). in the MN collection and supporting evidence in the
USC and OK datasets. As noted above, the HLA wasTwo of the significant regions reside on chromosome
1. The best evidence for linkage at 1q23 is the FcRIIa previously implicated in SLE by association studies, and
Immunity
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Table 3. Regions Demonstrating “Significant”1 Linkage in Human SLE2
Overlapping Autoimmune Interval
Primary LOD Supporting
Locus Score LOD Score(s) Candidate Genes Murine Model Other Autoimmune Disease(s)
1q22–24 OK 3.45 USC 1.513 FcRIIa Sle1a & Sle1b
(FcR) (D1S484) (NZM2410)
1q41–42 OK 3.50 USC2.403 PARP Sle1d (NZM2410) Type I diabetes,
(D1S3462) (D1S2785) Bxs3 (BXSB) Multiple Sclerosis,
MN 1.92 Rheumatoid Arthritis
(D1S235)
2q37 SW 4.24 OK 1.53 INPP5D Bxs1 (BXSB)
(D2S125) (D2S1363)
4p15–16 OK 3.84 MN 1.50 CD38, BST1, Sle6 (NZM2410)
(D4S2366) (D4S2366) ZNF36
6p11–22 MN 4.19 OK 1.70 HLA Class II Sles1 (NZM2410) Multiple autoimmune
(D6S426) (D6S2439) genes, C4a, TNF Lbw1 (NZB/NZW) diseases
SW 1.54
(D6S273)
16q12–13 MN 3.85 USC 1.003 NOD2 Crohn’s Disease,
(D16S415) (D16S3136) Psoriasis, Type I
diabetes
1 Recommended criteria for significant linkage in a genome-wide scan for a complex trait (LOD  3.3 for complex pedigrees, LOD  3.6 for
sib-pairs) (Lander and Kruglyak, 1995).
2 Shown are LOD scores (marker) meeting criteria for each interval. Supporting evidence (LOD  1.0) from an independent family collection
is also shown if present.
3 Z scores were converted to LOD scores by the equation: LOD  Z2/2ln10.
genes from this region appear to be important in the human SLE clearly indicates that multiple genes contrib-
ute to disease susceptibility in human and that suscepti-genetic susceptibility to many, if not all, autoimmune
diseases. Recent fine mapping across the HLA using a bility is inherited in a fashion similar to other complex
genetic diseases. However, some key features of SLEdense microsatellite screen in the MN family collection
has confirmed that the genetic effect is within the HLA genetics suggest that disease gene identification may
be more feasible in this system than in other autoimmuneitself, and dominant haplotypes have been identified
that show strong evidence for both linkage and associ- diseases. Although a relatively small number of families
have been screened thus far, several loci have beenation.
Finally, the 16q13 region provided a very strong link- detected that meet criteria for significant linkage, sug-
gesting that at least some of the genes mediating SLEage signal in the MN families, a finding supported by
data from the USC screen. Importantly, a susceptibility susceptibility in humans are quite potent. In addition, the
contribution of HLA to disease susceptibility, althoughgene for Crohn’s disease, an autoimmune inflammatory
disorder of the gut, was recently identified in the 16q13 significant, is of a similar magnitude to other susceptibil-
ity loci for SLE. Thus, the contribution of HLA to diseaseregion (Hugot et al., 2001; Ogura et al., 2001). NOD2 is
an LPS-responsive gene that influences NF-B signal- will not overwhelm the impact of other loci in linkage
analysis. Finally, several regions associated with sus-ing, and a frameshift polymorphism within the coding
region of the gene is strongly associated with suscepti- ceptibility in human studies are syntenic with genomic
segments identified by linkage analysis in mice (seebility to Crohn’s disease. The best evidence for linkage
in SLE at 16q13 is precisely at this locus, and NOD2 is Table 3). Although it is not known whether the same
genes are mediating disease in both species, the com-currently being examined in SLE families. The 16q13
region has also provided evidence for linkage in psoria- bined fine mapping analysis in both species should cross-
fertilize the process of candidate gene identification.sis, type I diabetes, and asthma, consistent with the
possibility that certain genes or gene clusters may pre-
dispose to different autoimmune diseases in humans Spontaneous Systemic Autoimmunity in the Mouse
Murine systemic autoimmunity has been recognized as(Becker et al., 1998).
In addition to these regions, which meet criteria for a model of human SLE for over 30 years, and the disease
has been extensively characterized in several inbred“significant” linkage, there are a large number of addi-
tional loci that show weaker, but suggestive, evidence strains (for review, see Theofilopoulos, 1995a, 1995b).
Although specific features of the disease vary amongfor linkage in SLE. The following regions have at least
nominal evidence for linkage in at least two independent lupus-prone strains, high-titered IgG autoantibodies
against a variety of nuclear autoantigens are consis-family collections: 1q31-32 (OK, SW), 2q32 (OK, MN),
3p21 (OK, USC), 6q26-27 (OK, SW), 9q13.3 (OK, SW), tently observed as an element in disease pathogenesis.
In addition, hypergammaglobulinemia, splenomegaly,11q23 (OK, SW), 13q31-32 (OK, MN), 18q21 (USC, SW),
20p12-13 (OK, MN), 20q11-13 (OK, MN), and 21q21 (OK, and expanded populations of activated CD4 T cells and
B cells are common disease features. Humoral autoim-USC).
In summary, the first wave of genomic screens in munity to nuclear antigens is often detectable within the
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first 4 to 6 months of age, and disease severity and nity. The yaa gene, which has not yet been identified,
is a novel and extremely intriguing gene capable of medi-incidence increases with age. Immune complex-medi-
ating very severe autoimmune phenotypes when incor-ated glomerulonephritis culminating in death due to kid-
porated into a permissive genome.ney failure is the most severe pathologic complication
The basis for disease susceptibility in all three of theseobserved among lupus-prone mice.
strains has been analyzed in multiple experimentalAlthough many parameters of systemic autoimmunity
crosses. Figure 1 summarizes the positions of all thein mice are similar to SLE in humans, there are also
susceptibility alleles that have been detected via linkageseveral differences. Severe pathogenesis is associated
analysis in both spontaneous and induced models ofwith the production of autoantibodies to double-stranded
SLE (Drake et al., 1994, 1995; Morel et al., 1994, 1999a;DNA (dsDNA) in both species; however, autoantibodies
Kono et al., 1994; Vidal et al., 1998; Vyse et al., 1996b;against many other nuclear antigens that are strongly
Haywood et al., 2000; Hogarth et al., 1998; Rozzo etassociated with disease in humans, such as Sm, Ro,
al., 1996, 2000). Thus far, more than 30 chromosomaland La, are not associated with lupus nephritis in mice.
regions containing genes impacting lupus susceptibilityAlso, the severe skin rashes that are often a defining
or resistance have been identified. For every strain ana-characteristic in human SLE are not observed in murine
lyzed, three or more intervals are associated with dis-models, undoubtedly due to dramatic species variations
ease susceptibility, indicating that murine lupus is ge-in the anatomy of the epidermis. Finally, the available
netically complex and mediated by combinations ofmouse models do not develop significant levels of many
genes. Interestingly, several of the susceptibility lociof the severe complications involving the brain and lung
mapped to similar locations across multiple strains,that are associated with human disease. This may be a
most notable in specific regions of chromosomes 1, 4,consequence of the relatively short duration of the dis-
7, and the MHC on chromosome 17. Although theseease in mice (6 months) relative to SLE in humans
results are intriguing and suggest that at least some(10 years). The extended disease course of SLE in
susceptibility genes may be shared between lupus-humans may mediate a steady deterioration of normal
prone strains, the majority of the intervals detected inimmune regulation in the immune system that ultimately
these crosses are strain specific. This indicates thatpotentiates the development of additional complica-
each lupus-prone strain is susceptible in part due to ations. Thus, murine models of systemic autoimmunity
unique set of disease genes, consistent with the pres-are probably most useful for the analysis of genetic
ence of extensive genetic heterogeneity in susceptibilitymechanisms that initiate the disease process and may
to murine lupus.not accurately reflect many of the complications that
A major strength of experimental models is the abilitydevelop in human SLE over extended periods of disease.
to utilize detailed phenotypic analysis together with so-
phisticated genetic crosses to analyze the locations andGenetic Dissection of Systemic Autoimmunity
component phenotypes of individual genes. CarefulThree spontaneous lupus-prone models have been ge-
analysis of individual elements in disease pathogenesis,netically characterized in detail in the mouse. These are:
such as the expression of autoantibodies to specific
(1) the (NZB X NZW)F1 hybrid (NZB/W) and the related
nuclear antigens and the severity of kidney glomerulone-
NZM2410 congenic recombinant strain, which is a clas-
phritis, has allowed some susceptibility alleles to be
sic model of spontaneous systemic autoimmunity; (2)
associated with the expression of specific components
the MRL/lpr strain, which carries the lpr spontaneous of disease pathogenesis. Thus, genes such as Sle1 and
mutation of the FAS receptor on an autoimmune-prone Nba2 in the telomeric region of chromosome 1 are
MRL background; and (3) the BXSB strain, which carries strongly associated with the production of autoantibod-
the Y chromosome autoimmune accelerator (yaa) gene ies to nuclear antigens (Vyse et al., 1996b, 1997; Morel
on the autoimmune-prone BXSB background. Each lu- et al., 1999a). Similarly, Nba1 on chromosome 4 is not
pus-prone strain has strengths and weaknesses as a associated with autoantibody production but instead is
model of autoimmunity and all vary with respect to their best correlated with the severity of glomerulonephritis
relevance to genetic mechanisms impacting human (Vyse et al., 1996a). Several other loci have been associ-
SLE. The NZB/W model is generally considered to most ated with mortality and lymphadenopathy (Vidal et al.,
closely reflect the properties of human SLE, in that this 1998; Kono et al., 1994). These types of analyses have
strain exhibits a strong female gender bias in suscepti- provided some insights into the roles that individual
bility and develops a severe systemic autoimmunity cul- genes may play in disease pathogenesis and indicate
minating in immune complex-mediated fatal glomerulo- that systemic autoimmunity is mediated by the interac-
nephritis. The MRL/lpr strain also develops systemic tions of several genes with distinct component pheno-
autoimmunity and glomerulonephritis, however, the lpr types.
mutation, which inactivates FAS-mediated apoptosis The most successful strategy to analyze the contribu-
and causes a profound lymphadenopathy, is a key ele- tion of individual susceptibility alleles to a multigenic
ment in the penetrance of disease pathogenesis. Al- trait such as systemic autoimmunity has been congenic
though the FAS pathway is an important regulatory path- dissection. This strategy, originally developed by George
way in the immune system, mutations in FAS are not Snell for the analysis of histocompatibility (Snell, 1948),
associated with susceptibility to human SLE. Suscepti- converts the polygenic system responsible for disease
bility to lupus in BXSB mice is limited to males because susceptibility into a series of monogenic systems via
the presence of a Y chromosome carrying yaa, which the production of individual congenic strains, each car-
interacts with several genes in the BXSB genome, is rying a single susceptibility interval on the resistant ge-
netic background. The component phenotypes medi-essential for the initiation of severe systemic autoimmu-
Immunity
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Figure 1. A Diagrammatic Representation of the Mouse Genome Illustrating the Locations of Lupus Susceptibility Genes
Lupus susceptibility loci (blue) are presented with their peak microsatellite markers and support intervals. Loci are from: Drake et al., 1994,
1995; Morel et al., 1994, 1999a; Kono et al., 1994; Vidal et al., 1998; Vyse et al., 1996b; Haywood et al., 2000; Hogarth et al., 1998; Rozzo et
al., 1996, 2000. The positions of suppressive modifiers are presented with black bars to define their support intervals (Morel et al., 1999a).
The positions of genes that have been reported to mediate systemic autoimmunity when disrupted are shown in red and their linkage positions
are from the Mouse Genome Database.
ated by each individual susceptibility gene can then some (Mohan et al., 1998). Sle2 lowers the activation
threshold of B cells, leading to polyclonal IgM antibodiesbe analyzed separately via the phenotypic analysis of
individual congenic strains. In addition, component phe- (Abs) and expansion of the B1a cell compartment (Mo-
han et al., 1997). Sle3 mediates a T cell dysregulationnotypes detected in individual congenic strains are ame-
nable to genetic and functional analysis as Mendelian that is associated with polyclonal IgG Abs and a de-
crease in activation-induced cell death in CD4 T cellstraits, thus making traditional fine mapping and subse-
quent positional cloning strategies feasible. (Mohan et al., 1999b).
Although the B6.Sle congenic strains express compo-The most extensive use of congenic dissection to
investigate the properties of individual susceptibility al- nent phenotypes relevant to autoimmunity, none de-
velop severe pathology, indicating that the individualleles in lupus-prone strains has been with the NZM2410
strain (Morel et al., 1997; Wakeland et al., 1997). Suscep- genes are not sufficient to cause lupus. To assess the
fashion in which these genes interact to mediate moretibility to lupus in NZM2410 is predominantly due to
genes localized to the telomeric region of chromosome severe autoimmune phenotypes, the individual con-
genic intervals were reassembled in various combina-1 (Sle1), the middle of chromosome 4 (Sle2), and the
centromeric segment of chromosome 7 (Sle3) (Morel et tions on the B6 background (Mohan et al., 1999a; Morel
et al., 2000). Interestingly, the coexpression of Sle1, Sle2,al., 1994). Congenic strain construction was performed
by transferring each of these intervals from NZM2410 and Sle3 as a B6-triple congenic results in severe sys-
temic autoimmunity and fully penetrant, fatal glomerulo-onto the B6 background, and phenotypic analysis re-
vealed that each locus contributes a unique component nephritis (Morel et al., 2000). These results demonstrate
the fulfillment of the genetic equivalent of Koch’s postu-phenotype to disease pathogenesis (Morel et al., 1997).
Sle1 mediates the loss of tolerance to nuclear antigens late, where susceptibility loci in a lupus-prone strain
have been identified by a genome scan, isolated andwith a high specificity for the H2A/H2B/DNA subnucleo-
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functionally characterized by congenic dissection, and strains provide a clear illustration of synergism between
susceptibility alleles for lupus. B6.Sle1 and B6.yaa spon-finally shown to mediate full disease expression when
recombined in a normal genome. This analysis addition- taneously produce nonpathogenic autoantibodies to
nuclear antigens, but fail to develop severe autoimmu-ally demonstrated that Sle1, which breaks tolerance to
chromatin antigens, was essential for the development nity. However, when these two susceptibility alleles are
combined in the B6.Sle1/yaa bicongenic strain, a severeof fatal lupus nephritis in the B6-congenic model system
since only combinations of intervals that included Sle1 systemic autoimmunity develops, culminating in fatal
glomerulonephritis with an incidence of 70% by 9developed severe lupus nephritis.
A fine mapping analysis of the Sle1 congenic interval months of age (Morel et al., 2000). This illustrates an
epistatic interaction between two susceptibility alleleswas recently completed, and this analysis has revealed
that a single susceptibility interval can be highly com- that causes a greater increase in disease severity than
would be predicted by simply adding their individualplex (Morel et al., 1999a, 2000). Phenotypic analysis
of over 250 recombinants spaced throughout the Sle1 phenotypes together.
A second type of epistasis, in which epistatic modifi-congenic interval detected four separate susceptibility
loci; three capable of breaching humoral immune toler- ers suppress the autoimmune phenotypes of suscepti-
bility alleles, has also been detected using the B6.Sleance to chromatin antigens and one mediating severe
glomerulonephritis when combined with other suscepti- congenic strains (Morel et al., 1999b). Genes capable
of suppressing autoimmunity were detected via thebility alleles in a permissive genome (Morel et al., 2000).
Thus, the “Sle1” phenotype actually represents the com- analysis of the disease phenotype mediated by Sle1,
Sle2, and Sle3 when introgressed onto different geneticbined effects of four separate loci, each contributing a
subset of the component phenotypes detected in backgrounds. As discussed above, B6.Sle1/Sle2/Sle3
triple congenic mice develop fatal lupus nephritis withB6.Sle1. The detection of a cluster of genes mediating
a complex trait phenotype, rather than a single gene, a penetrance approaching 100% in both genders by 9
months of age (Morel et al., 2000). Interestingly, all threehas been a consistent observation of fine mapping stud-
ies on individual loci contributing to autoimmune dis- of these susceptibility alleles are derived from the NZW
genome, and yet, as discussed above, NZW exhibitsease (for review, see Wandstrat and Wakeland, 2001).
As listed in Table 3, Sle1a and Sle1b localize into regions only very benign autoimmune phenotypes in females
greater than 12 months of age (Kelley and Winkelstein,syntenic with 1q21-23, and Sle1d into a region syntenic
with 1q41. Thus, the Sle1 cluster appears to contain 1980). Thus, the phenotypic expression of Sle1/Sle2/
Sle3 is significantly suppressed in NZW. A linkage analy-genes that are syntenic with two of the six human inter-
vals that exhibit significant linkage with susceptibility to sis found four separate loci that accounted for the sup-
pression of lupus susceptibility in NZW (Morel et al.,SLE. These results raise the possibility that similar genes
or possibly a gene family are responsible for susceptibil- 1999b). These results indicate that the disease mediated
by susceptibility genes can be fully suppressed by otherity to systemic autoimmunity in both mice and humans,
although further work will be necessary to delineate the “modifying” genes in the genome. Interestingly, Sles1,
which is the most potent suppressive modifier detectedrelationship of the Sle1 gene cluster with SLE suscepti-
bility genes in human 1q23 and 1q41. in this analysis, was shown to specifically suppress the
autoimmune phenotype of Sle1. This result is especially
intriguing because Sles1 is located in close proximityEpistatic Interactions and Systemic Autoimmunity
to the murine MHC, which places it in an area that isEpistasis is classically defined as a genetic interaction in
syntenic with another potent SLE susceptibility intervalwhich the genotype at one locus affects the phenotypic
detected by human linkage analysis of SLE (Table 3).expression of the genotype at another locus (Suzuki et
Although the extent of epistasis in human SLE remains toal., 1989). The importance of epistasis in the develop-
be determined, it is reasonable to predict that epistaticment of severe systemic autoimmunity was apparent
interactions are a consequence of the many functionalearly in the analysis of lupus-prone mouse models, in
polymorphisms impacting immune recognition and re-that (NZB X NZW)F1 hybrid mice were found to develop
sponsiveness and will therefore be a component of SLEsevere systemic autoimmunity, although both parental
susceptibility in most species.strains were not severely autoimmune. Thus, genetic
interactions between alleles in NZB and NZW resulted
in the expression of a phenotype (severe systemic auto- Genetic Pathways Implicated by Synthetic
Models of Autoimmunityimmunity), which was absent in both parental strains.
Similarly, the lpr spontaneous mutation of Fas, which is A collection of synthetic models of autoimmunity have
been created via targeted genetic disruptions of specifica potent autoimmune susceptibility gene in the MRL/
lpr lupus model, lost its autoimmune phenotype when regulatory genes in the immune system and/or the cre-
ation of transgenic strains with aberrant/overexpressionintrogressed onto other genetic backgrounds (Fossati
et al., 1993; Warren et al., 1984). Similar findings have of regulatory pathways. The strength of this approach
is that it allows an in vivo assessment of the impact ofbeen made with the yaa gene in BXSB. These relation-
ships illustrate that the autoimmune potential of specific severe modifications in the expression of these genes on
the immune system. In addition, these synthetic modelssusceptibility genes is exquisitely dependent upon the
presence of a “permissive” genome to potentiate the can be used in some instances to characterize an ef-
fector mechanism involved in disease pathogenesisexpression of an autoimmune phenotype.
The spontaneous autoimmune phenotypes of the con- and/or to delineate genetic mechanisms that will lead
to systemic autoimmunity.genic B6.Sle1, B6.yaa, and bicongenic B6.Sle1/yaa
Immunity
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Table 4. Candidate Genes and Pathways Implicated in SLE
Proposed Mechanism Murine SLE Human SLE
Antigen/Immune complex clearance C1q knockout C1q
C3, C4 knockout C2, C3, C4
Sap1 knockout Mannose binding protein
DNAse I knockout FcRIIA
Serum IgM knockout FcRIIIA
Fc common chain knockout DNAse I
Mer knockout
Lymphoid signaling SHP-1 knockout T cell receptor 	 chain
Lyn knockout TNF

Lyn/Fyn double knockout IL-10
CD22 knockout
BlyS transgenic
PD-1 knockout
IL-2 knockout
CD45 E613R point mutation
G2A knockout
IFN-gamma transgenic
Apoptosis Fas knockout
Fas-L knockout
Bcl-2 transgenic
Pten2 heterozygous deficiency
p21 cyclin dependent kinase knockout
Epitope modification 
-Mannosidase II knockout
1 Serum Amyloid P-component.
2 Phosphatase and tensin homolog.
Table 4 provides a listing of modified genes that have of either Serum amyloid P component (SAP) (Bickerstaff
et al., 1999), a protein involved in the metabolism ofbeen reported to mediate some level of systemic auto-
immunity and their locations in the mouse genome are chromatin, or DNase I (Napirei et al., 2000), a molecule
potentially involved in chromatin metabolism, both leadpresented in Figure 1. These genes can be organized
into four broadly defined pathways impacting immune to modest levels of systemic autoimmunity. Interest-
ingly, polymorphisms in the DNase I gene have recentlyfunctions relevant to systemic autoimmunity. The first
pathway affects the clearance of nuclear chromatin or been detected in SLE patients, suggesting that polymor-
phisms in this gene may also potentiate SLE in humansimmune complexes. Deficiencies in C1q, C3, and C4
have all been shown to mediate the development of (Yasutomo et al., 2001). These findings further support
the conjecture that modifications in chromatin metabo-various levels of humoral autoimmunity to nuclear anti-
gens. The targeted disruption of the C1q gene by Wal- lism may predispose for the development of humoral
autoimmunity to nuclear chromatin (Walport, 2000).port and coworkers was the first complement compo-
nent deficiency to be shown to mediate systemic The second pathway potentiating the development of
systemic autoimmunity includes cytokines and signalautoimmunity (Botto et al., 1998). Pathologic studies
also revealed that large numbers of apoptotic cells accu- transduction molecules that regulate immune activation.
Targeted disruptions of SHP-1, Lyn, CD22, PD-1, IL-2,mulated in diseased glomeruli, supporting the hypothe-
sis that C1q may have a critical role to play in the physio- G2A, the Fc common subunit, and CD45 all have been
shown to cause varying levels of humoral autoimmunitylogical clearance of apoptotic cells. Kelsoe and colleagues
recently reported that the targeted disruption of the gene to nuclear antigens, especially when bred onto permis-
sive genetic backgrounds (Nishimura et al., 1999; Cor-encoding C4 led to the spontaneous development of
lupus-like autoimmunity, a result very similar to that for nall et al., 1998; Bolland and Ravetch, 2000). Transgenic
dysregulation of BlyS and IFN have a similar effectC1q (Chen et al., 2000). These results document the
ability of deficiencies in multiple complement compo- (Khare et al., 2000). A third pathway impacting systemic
autoimmunity involves a collection of genes with variousnents to mediate a breach in humoral tolerance to nu-
clear antigens (Carroll, 2000; Chen et al., 2000). Although roles in the regulation of apoptosis. As discussed above,
disruptions of the FAS pathway are known to dramati-the precise pathway involved is unclear, a role for the
CR1/CR2 receptors was excluded via the analysis of a cally impact autoimmunity in the MRL background. A
dysregulated bcl-2 transgene also was reported toCr2/ mutant, which failed to develop autoimmunity
(Applequist et al., 2000). Some investigators have postu- breach tolerance to nuclear antigens, at least when bred
onto specific backgrounds (Mandik-Nayak et al., 2000).lated that these complement components play a role in
the physiology and metabolism of apoptotic cells and/ Finally, targeted disruptions of genes impacting glyco-
sylation have been shown to mediate a strong systemicor chromatin and that their deficiency leads to the gener-
ation of an autoimmune-prone B cell receptor repertoire autoimmunity (Chui et al., 2001). The precise molecular
mechanism responsible for this effect remains to beduring B cell ontogeny (Carroll, 1998a). Although intri-
guing, this hypothesis lacks formal proof. However, re- elucidated.
Perhaps the most puzzling aspect of the results withcently other investigators have shown that deficiencies
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way, genes like Sle2, Sle3, Fas, FasL, yaa, lyn, Blys, Il2,
and pd-1 participate in the process of hypersensitization
and/or disruption of the normal immune system, leading
to immune dysregulation. Some genes in this pathway
are capable of causing the initiation of a humoral autoim-
mune response to nuclear antigens that is minimally
pathogenic. When added to a gene in the first pathway,
however, they will mediate a transition to pathogenic
autoimmunity to nuclear antigens (Mohan et al. 1999a).
Finally, FcIIIa, Sle6, and Sle1d are genes that we would
propose to be involved in the final step of the pathway.
Genes in this step mediate ANA targeting into the spe-
cific organ to promote end organ culmination. Theoreti-
cally, end organ damage, for example of the kidney, can
be mediated by a variety of factors, including molecules
or mechanisms that affect or dictate glomerular archi-
tecture, the structural and chemical makeup of the base-
ment membrane, local inflammatory processes, local
cytokine production, and miscellaneous factors that
control immune complex clearance.
Future Prospects for Genetic Analysis of SLE
A crucial goal for future efforts in the genetics of SLE
will be to transition from linkage analysis into gene iden-
Figure 2. A Hypothetical Pathway Illustrating the Manner in which tification and the characterization of genetic mechanisms
Individual Susceptibility Genes Interact to Potentiate Severe Auto- mediating autoimmunity. The recent publication of an
immunity almost complete nucleotide sequence of the human ge-
nome has provided detailed physical and molecular
maps of the majority of human linkage groups (Venter
targeted genetic disruptions is the overall frequency et al., 2001). In addition, a growing database of single-
with which these manipulations have revealed a predis- nucleotide polymorphisms (SNPs) together with an im-
position to systemic autoimmunity. In this regard, three proving technology for their detection will greatly en-
separate reports have clearly documented that B6 X 129 hance the statistical power of linkage analysis (Halushka
hybrid genomes are spontaneously predisposed to the et al., 1999; Cargill et al., 1999). These technological
development of humoral autoimmunity with low levels advances in molecular genetics should provide the tools
of glomerulonephritis, especially in aged females (Botto needed to begin to delineate the genetic mechanisms
et al., 1998; Bickerstaff et al., 1999; Santiago-Raber et responsible for susceptibility to SLE in human popula-
al., 2001). As a result, both control and experimental tions. However, the complexity of inheritance and ge-
mice would be predicted to express a background level netic heterogeneity of SLE susceptibility remains a
of systemic autoimmunity when targeted disruptions are daunting challenge, and success in the identification of
tested in mice segregating a mixture of the B6 and 129 susceptibility alleles in human populations will probably
genomes (a very common situation). In fact, a recent await the development of more powerful analytical pro-
analysis of a p21 disruption reported a much less robust cedures and larger patient populations.
association with systemic autoimmunity than was pre- The identification of lupus susceptibility genes in ani-
viously described, predominantly due to the use of ap- mal models, on the other hand, is clearly imminent. Con-
propriate control animals (Santiago-Raber et al., 2001). genic dissection is a powerful tool that has allowed
Given these findings, the impact of epistatic interactions susceptibility genes to be precisely localized into inter-
between the B6 and 129 genomes on systemic autoim- vals as small as 800–1000 kb (Lyons et al., 2000; Morel
munity should be carefully assessed when analyzing the et al., 2001). The soon to be completed mouse genome
autoimmune phenotypes of specific genetic disruptions. project will dramatically simplify the identification of po-
sitional candidates in these intervals, and definitive gene
involvement can be determined through in vivo comple-Genetic Interactions during SLE Pathogenesis
A three-step hypothetical model of the roles that various mentation using BAC transgenic technologies (Antoch
et al., 1997; Probst et al., 1998). Targeted mutagenesisgenetic pathways play in the initiation of SLE pathogene-
sis is presented in Figure 2. The development of SLE in BACs and/or ES cells can also help to definitively
identify specific positional candidates as susceptibilitycan be viewed as involving interactions between genes
in three separate pathways. The first pathway contains genes.
Finally, the use of gene expression microarrays togenes such as Sle1, C1q, C4, SAP, and DNase that can
trigger the loss of immune tolerance to nuclear autoanti- identify genes whose expression is modified by SLE
susceptibility alleles has the potential to revolutionizegens and mediate the initiation of autoimmunity. In this
regard, many first-degree relatives of SLE probands ex- mapping strategies for complex traits. Theoretically, this
technology should identify genes that are dysregulatedhibit a similar seropositive phenotype without severe
disease pathogenesis. At the second step of the path- during the initiation of systemic autoimmunity, thus pro-
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